Severe Hidradenitis Suppurativa (HS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Severe Hidradenitis Suppurativa (HS) Market Outlook

Thelansis’s “Severe Hidradenitis Suppurativa (HS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Hidradenitis Suppurativa (HS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Severe Hidradenitis Suppurativa (HS) Overview

Hidradenitis suppurativa (HS), also known as acne inversus, is a chronic inflammatory skin disorder characterized by lesions such as deep-seated nodules, abscesses, draining tracts, and fibrotic scars. These lesions typically develop in areas where skin rubs together or where there are many sweat glands, with common sites including the axillary, groin, perianal, perineal, and inframammary regions. Depending on the stage of the disease, individuals may experience painful, tender papules, cysts, or nodules, along with areas of scar tissue. The condition may also involve the discharge of foul-smelling pus from the skin and the formation of sinus tracts under the skin. While there is no cure for HS, various treatment options are available based on the severity of the condition. For mild to moderate cases, treatment may involve the use of antibiotic creams, lotions, or washes, oral antibiotics, local steroid injections, minor surgical procedures, laser therapy, and hormone-regulating medications. In cases of more severe disease, these treatments may still be beneficial, along with injectable biologic agents, more extensive surgical procedures, oral immunosuppressive drugs, and other systemic medications.

  • The prevalence of hidradenitis suppurativa is estimated to range from 0.5% to 4%, affecting approximately 11 in 100,000 individuals in the United States. Females are more commonly affected than males.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Severe Hidradenitis Suppurativa (HS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment